In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine
- PMID: 2088769
- DOI: 10.1007/BF03190222
In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine
Abstract
Vinblastine and Vincristine pharmacokinetics, including tissue distribution, metabolism and biliary excretion, were investigated, using both "in vitro" and "in vivo" models, after i.v. injections in rats. Plasma kinetic curves were best fitted to a two-compartment open model. The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively. The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg. VCR was found to be widely distributed in tissues after i.v. injections in rats. The highest drug accumulation site was the intestine (122.0 ng/g wet tissue at 24 h). Liver and kidneys also retained high proportions of drug (respectively, 47.0 ng/g and 44.4 ng/g at 24 h). Biliary excretion was more rapid for VCR (42.7% of total radioactivity excreted over 24 h) than VLB (28.2% of total dose over 24 h). For both molecules, the percentage of radioactivity excreted in bile over 30-48 h ranged between 40-50% of total dose. At high doses, either biliary excretion rate or cumulated excretion was reduced. High performance liquid chromatography analysis of bile samples revealed four biotransformation products for VLB and three for VCR. When incubated in freshly isolated rat hepatocytes, VLB penetrated more rapidly and intensely into the cells (more than 90% of total dose taken up over 20 min) than VCR (only about 40% accumulated), probably through a passive diffusion mechanism followed by tight cellular binding. "In vitro" metabolism patterns were similar to those found "in vivo", except for the most polar metabolites observed "in vitro". Two anti-Vinca monoclonal antibodies with different specificities were used to test VCR metabolite immunoreactivities. The results suggested that some structural modifications occurred in the catharantine moiety of the molecule but that the dimeric structure seemed to be well conserved after biotransformation.
Similar articles
-
In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide).Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):49-55. doi: 10.1007/BF03190127. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2384117
-
Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.Arzneimittelforschung. 1993 Dec;43(12):1367-77. Arzneimittelforschung. 1993. PMID: 8141830
-
Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.Cancer Chemother Pharmacol. 1992;29(5):367-74. doi: 10.1007/BF00686005. Cancer Chemother Pharmacol. 1992. PMID: 1551175
-
Clinical pharmacokinetics of vinorelbine.Clin Pharmacokinet. 1996 Sep;31(3):184-97. doi: 10.2165/00003088-199631030-00003. Clin Pharmacokinet. 1996. PMID: 8877249 Review.
-
Pharmacokinetics and metabolism of Navelbine.Semin Oncol. 1989 Apr;16(2 Suppl 4):21-5. Semin Oncol. 1989. PMID: 2652317 Review. No abstract available.
Cited by
-
The effect of increased lipoproteins levels on the disposition of vincristine in rat.Lipids Health Dis. 2016 Sep 9;15(1):152. doi: 10.1186/s12944-016-0318-0. Lipids Health Dis. 2016. PMID: 27613245 Free PMC article.
-
Composite Hydrogels with Included Solid-State Nanoparticles Bearing Anticancer Chemotherapeutics.Gels. 2023 May 17;9(5):421. doi: 10.3390/gels9050421. Gels. 2023. PMID: 37233012 Free PMC article. Review.
-
Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors.ACS Omega. 2019 Jun 4;4(6):9784-9799. doi: 10.1021/acsomega.9b00652. eCollection 2019 Jun 30. ACS Omega. 2019. PMID: 31460070 Free PMC article.
-
Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.Pharm Res. 2017 Nov;34(11):2336-2348. doi: 10.1007/s11095-017-2241-0. Epub 2017 Aug 21. Pharm Res. 2017. PMID: 28828541
-
High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Posaconazole and Vincristine in Rat Plasma.Int J Anal Chem. 2015;2015:743915. doi: 10.1155/2015/743915. Epub 2015 Dec 22. Int J Anal Chem. 2015. PMID: 27034675 Free PMC article.